Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, orthopedic and surgical products maker Orthovita (NASDAQ:VITA) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Orthovita's business and see what CAPS investors are saying about the stock right now.

Orthovita facts

Headquarters (founded)

Malvern, Pa. (1992)

Market Cap

$406.3 million

Industry

Health Care Equipment

Trailing-12-Month Revenue

$82.44 million

Management

President/CEO Anthony Koblish (since April 2002)

CFO Nancy Broadbent (since May 2009)

Compound Annual Revenue Growth (over last five years)

36.6%

Competitors

Stryker (NYSE:SYK)

Osteotech

CAPS Members Bullish on VITA Also Bullish on

General Electric (NYSE:GE)

Apple (NASDAQ:AAPL)

Google (NASDAQ:GOOG)

CAPS Members Bearish on VITA Also Bearish on

Citigroup (NYSE:C)

Ford Motor (NYSE:F)

Sources: Capital IQ (a division of Standard & Poor's), and Motley Fool CAPS.

Over on CAPS, 169 of the 179 members who have rated Orthovita -- some 94% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Stars PhillyDan and TSIF, both of whom are ranked in the top 15% of our community.

Just last week, PhillyDan touched on the supertrend working in the stock's favor:

With aging baby boomers, Orthovita's unique medical implant devices will become more of a fixture to repair bone fractures for bone compression injuries. In addition, their Vitagel and Vitasure products will be employed widely in surgeries to help stop bleeding and decrease healing time.

In a pitch from the same day, TSIF made no bones about the bull case:

Orthovita has been in the "bone surgery" business for several years … Although it's also coming off of a losing quarter, and has spent the last three years near break-even, I very much like what I see. FDA approval of CORTOSS, an injectable bone replacement composite was just achieved … according to Orthovita, (as you would expect), their data indicates that Cortoss is easier to use, more effective, and will be preferred by surgeons in the delicate spine/fracture/compression operations … With some insider ownership, debt below cash on hand, and revenues that already came very close to paying the bills, the new addition to their lineup should make them a good value play and possible a nice long in a somewhat recession proof portfolio.

What do you think about Orthovita, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.